MedTrace Logo

The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting

NCT07021443 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-08-26

Study results available
· View outcomes & findings →

Summary

This study aims to measure the effect of GLP-1 analogues on non-alcoholic fatty liver disease in patients with diabetes and/or obesity in a clinical context. Previous studies showed a positive effect of this medication, but these studies always took place in highly controlled settings. The question is to what extent liver values evolve in a non-controlled context. The real effect and thus the clinical utility of GLP-1 analogues will be measured.

Conditions

  • Non-Alcoholic Fatty Liver Disease

Interventions

OTHER

non-interventional

non-interventional

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-09
Primary Completion
2023-10-26
Completion
2025-05-12

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021443 on ClinicalTrials.gov